An overview of PsoProtect’s current data.

Current Data

We are committed to sharing data and are delighted to provide open access to summary data of the cases in PsoProtect. These data are preliminary and include a limited number of cases, so should not be used to inform clinical decision making.

Click here to read our scientific research paper detailing the PsoProtect data, entitled ‘Factors associated with adverse COVID-19 outcomes in patients with psoriasis – insights from a global registry-based study‘.

0
Total number of cases reported

Summary data from PsoProtect’s first 1249 cases.

Cases reported by country of assessment (≥20 cases):
Country Cases
United Kingdom 339
France 187
Italy 150
Spain 114
Netherlands 94
Portugal 57
United States 48
Hungary 48
Poland 32
Argentina 29
Belgium 20
Rest of the world 131

Average age: 49 years
Phenotype of psoriasis: 1222 plaque psoriasis, 27 pustular psoriasis
Average BMI: 27.6 kg/m2
Average number of days of symptoms from COVID-19: 11 days

Confirmed COVID-19:

Gender:

Smoking history:

Concurrent psoriatic arthritis:

Severity of psoriasis at time of onset of COVID-19 (PGA):

Hospitalization required due to COVID-19:

Systemic medication for psoriasis at time of onset of COVID-19:

Medication Count
Biologic – TNF inhibitor 303
Biologic – IL-23 inhibitor 332
Biologic – IL-17 inhibitor 200
Conventional systemic agent 155
Small molecule inhibitor 48
Biologic and conventional systemic co-therapy 38
Small molecule inhibitor and conventional systemic co-therapy 4
No systemic agent 165
Unknown (participating in clinical trial) 4

Was the biologic medication for psoriasis stopped during COVID-19 infection:

Outcome of COVID-19: